Axitinib

Common brands: Inlyta, Keytruda, Bavencio, Katerzia, Norliqva

Top reporter: Pfizer Laboratories Div Pfizer Inc

Kinase Inhibitor [EPC]Programmed Death Receptor-1 Blocking Antibody [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Programmed Death Ligand-1 Blocker [EPC]Corticosteroid [EPC]
19,195
Total Reports
10,700
Serious Reports
3,860
Death Reports
30
Reported Reactions
Death Report Ratio: High (20.11%)

Patient Demographics

Male
12,537
Female
5,168

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Axitinib.

# Reaction Reports % of Total
1 DEATH 2,635
10.2%
2 DIARRHOEA 2,565
10.0%
3 FATIGUE 2,106
8.2%
4 NEOPLASM PROGRESSION 1,323
5.1%
5 HYPERTENSION 1,321
5.1%
6 DISEASE PROGRESSION 1,211
4.7%
7 OFF LABEL USE 1,200
4.7%
8 NAUSEA 1,142
4.4%
9 DECREASED APPETITE 1,083
4.2%
10 DYSPHONIA 1,009
3.9%
11 BLOOD PRESSURE INCREASED 848
3.3%
12 WEIGHT DECREASED 798
3.1%
13 ASTHENIA 758
2.9%
14 HEADACHE 604
2.3%
15 STOMATITIS 591
2.3%
16 VOMITING 575
2.2%
17 MALAISE 529
2.1%
18 CONSTIPATION 520
2.0%
19 PAIN 517
2.0%
20 DYSPNOEA 512
2.0%
21 RASH 479
1.9%
22 PAIN IN EXTREMITY 451
1.8%
23 PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME 450
1.7%
24 ARTHRALGIA 442
1.7%
25 DEHYDRATION 383
1.5%
26 MALIGNANT NEOPLASM PROGRESSION 366
1.4%
27 RENAL CANCER 354
1.4%
28 DIZZINESS 333
1.3%
29 PRODUCT DOSE OMISSION ISSUE 317
1.2%
30 HYPOTHYROIDISM 312
1.2%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.